全文获取类型
| 收费全文 | 21682篇 |
| 免费 | 558篇 |
| 国内免费 | 174篇 |
专业分类
| 耳鼻咽喉 | 66篇 |
| 儿科学 | 1147篇 |
| 妇产科学 | 774篇 |
| 基础医学 | 2969篇 |
| 口腔科学 | 234篇 |
| 临床医学 | 1163篇 |
| 内科学 | 5741篇 |
| 皮肤病学 | 352篇 |
| 神经病学 | 1777篇 |
| 特种医学 | 662篇 |
| 外国民族医学 | 1篇 |
| 外科学 | 3504篇 |
| 综合类 | 688篇 |
| 预防医学 | 792篇 |
| 眼科学 | 319篇 |
| 药学 | 1145篇 |
| 2篇 | |
| 中国医学 | 275篇 |
| 肿瘤学 | 803篇 |
出版年
| 2023年 | 107篇 |
| 2022年 | 231篇 |
| 2021年 | 366篇 |
| 2020年 | 248篇 |
| 2019年 | 1423篇 |
| 2018年 | 1354篇 |
| 2017年 | 632篇 |
| 2016年 | 227篇 |
| 2015年 | 281篇 |
| 2014年 | 427篇 |
| 2013年 | 444篇 |
| 2012年 | 386篇 |
| 2011年 | 417篇 |
| 2010年 | 311篇 |
| 2009年 | 299篇 |
| 2008年 | 310篇 |
| 2007年 | 294篇 |
| 2006年 | 303篇 |
| 2005年 | 246篇 |
| 2004年 | 224篇 |
| 2003年 | 225篇 |
| 2002年 | 174篇 |
| 2001年 | 152篇 |
| 2000年 | 116篇 |
| 1999年 | 114篇 |
| 1998年 | 94篇 |
| 1997年 | 92篇 |
| 1996年 | 82篇 |
| 1995年 | 69篇 |
| 1994年 | 62篇 |
| 1993年 | 59篇 |
| 1992年 | 43篇 |
| 1991年 | 61篇 |
| 1990年 | 47篇 |
| 1989年 | 40篇 |
| 1988年 | 31篇 |
| 1987年 | 43篇 |
| 1985年 | 1059篇 |
| 1984年 | 1784篇 |
| 1983年 | 1149篇 |
| 1982年 | 1241篇 |
| 1981年 | 1205篇 |
| 1980年 | 998篇 |
| 1979年 | 897篇 |
| 1978年 | 830篇 |
| 1977年 | 704篇 |
| 1976年 | 798篇 |
| 1975年 | 556篇 |
| 1974年 | 505篇 |
| 1973年 | 559篇 |
排序方式： 共有10000条查询结果，搜索用时 968 毫秒
1.
Noreen M. Walsh Heinz Kutzner Luis Requena Lorenzo Cerroni 《Journal of cutaneous pathology》2019,46(9):698-708
We review the spectrum of cutaneous disorders associated with inflammatory and neoplastic plasmacytic pathology. Because plasma cells are derived from B‐lymphocytes our overview includes discussion of certain lymphoplasmacytic proliferations. It is structured along histopathological lines, addressing conditions characterized by (a) cutaneous plasma cell infiltrates, (b) deposits of plasma cell products or their derivatives in the skin and (c) miscellaneous, poorly understood cutaneous complications of plasmacytic disorders. Lesions arising primarily in the skin and those due to cutaneous involvement by multisystem disorders are addressed. The range includes a spectrum of tumefactive and circulatory manifestations. We highlight key clinical and pathological features of the different conditions and outline recent advances in our understanding of these entities. By emphasizing the dermatopathological characteristics of this spectrum of disorders we hope to hone the diagnostic accuracy of practitioners in the field. 相似文献
2.
3.
Ahmed M. Abu El-Asrar Ajmal Ahmad Eef Allegaert Mohammad Mairaj Siddiquei Priscilla W. Gikandi Gert De Hertogh 《Ocular immunology and inflammation》2020,28(4):575-588
ABSTRACT
Purpose
To investigate the expression of IL-11 and its receptor IL-11Rα and to quantify density of CD163+ M2 macrophages in proliferative diabetic retinopathy (PDR). 相似文献4.
5.
Conall T. Morgan Brigitte Mueller Varsha Thakur Vitor Guerra Callaghan Jull Luc Mertens Mark Friedberg Fraser Golding Mike Seed Steven E.S. Miner Edgar T. Jaeggi Cedric Manlhiot Lynne E. Nield 《The Canadian journal of cardiology》2019,35(4):453-461
Background
The purpose of the study was to evaluate the association between fetal echocardiographic measurements and the need for intervention (primary coarctation repair, staged coarctation repair, or catheter intervention) in prenatally diagnosed coarctation of the aorta.Methods
A single-centre retrospective cohort study (2005-2015) of 107 fetuses diagnosed with suspected coarctation of the aorta in the setting of an apex-forming left ventricle and antegrade flow across the mitral and aortic valves.Results
Median gestational age at diagnosis was 32 weeks (interquartile range, 23-35 weeks). Fifty-six (52%) did not require any neonatal intervention, 51 patients (48%) underwent a biventricular repair. In univariable analysis, an increase in ascending aorta (AAo) peak Doppler flow velocity (odds ratio [OR], 1.40 [95% confidence interval [CI], 1.05-1.91] per 20 cm/s; P = 0.03) was associated with intervention. No intervention was associated with larger isthmus size (OR, 0.23; P < 0.001), transverse arch diameter (OR, 0.23; P < 0.001), and aortic (OR, 0.72; P = 0.02), mitral (OR, 0.58; P = 0.001), and AAo (OR, 0.53; P < 0.001) z-scores. In multivariable analysis, higher peak AAo Doppler (OR, 2.51 [95% CI, 1.54-4.58] per 20 cm/s; P = 0.001) and younger gestational age at diagnosis (OR, 0.81 [95% CI, 0.70-0.93] per week; P = 0.005) were associated with intervention, whereas a higher AAo z-score (OR, 0.65 [95% CI, 0.43-0.94] per z; P = 0.029) and transverse arch dimension (OR, 0.44 [95% CI, 0.18-0.97]; P = 0.05) decreased the risk of intervention.Conclusions
In prenatally suspected coarctation, the variables associated with intervention comprised smaller AAo and transverse arch size, earlier gestational age at diagnosis, and the additional finding of a higher peak AAo Doppler. 相似文献6.
7.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献8.
9.
10.